SBIR Success Stories: 7 Companies That Won Big
Updated 12 official sources
Quick Answer: More than $4 billion flows through SBIR/STTR annually across 11 federal agencies, and the 2026 reauthorization extended the programs through September 30, 2031.
Full answer and how we checked it
This guide is for startup founders, R&D leads, university spinouts, and technical small businesses studying SBIR success stories before deciding whether SBIR fits their commercialization strategy. SBIR success stories include major wins like Qualcomm, iRobot, Symantec, 23andMe, and Martek, but the lesson is not that every award becomes a giant company. The useful pattern is that successful teams used SBIR to reduce a specific technical risk, then moved toward Phase III, private capital, procurement, licensing, or a real customer.
Who this is for: If you're a startup founder, R&D director, or technology entrepreneur considering SBIR funding, this article shows you what actually works. These aren't theoretical case studies. They're real companies that used SBIR grants to build products, attract investors, and create lasting businesses. You'll walk away knowing what separates the SBIR success stories worth studying from the companies that collected awards and went nowhere.
Data note: SBIR/STTR authorization, agency examples, commercialization reporting, and company-status facts were checked against SBIR.gov, NIH SEED, NSF America's Seed Fund, DOE SBIR/STTR, FTC, Amazon, iRobot filings, the White House signing notice, and 23andMe investor materials on June 18, 2026. Company award histories and status were rechecked October 9, 2026 against NSF, NIH RePORTER, SBA, and DOE records. Program parameters may change with appropriations and agency policy updates.
In this guide
- June 2026 Source Check: Success Stories Need Status Repair
- Current Success-Story Decision Screen
- May 2026 Grantsights Decision Memo: Read Success Stories as Transition Evidence
- The SBIR Success Stories Hall of Fame: 7 Companies Worth Studying
- Best Fit and Bad Fit Checklist for Studying SBIR Success Stories
- Qualcomm: The Large-Cap SBIR Success Story
- iRobot: From Military Robots to Roomba
- Symantec: An NSF SBIR That Led Somewhere Unexpected
- 23andMe: NIH SBIR Funding Meets Consumer Genomics
- Martek, Giner, and Invocon: Smaller Stories Worth Studying
- 5 Patterns That SBIR Success Stories Share
- The SBIR Hall of Fame: What It Takes to Get Recognized
- How to Build a Commercialization Track Record From Your First SBIR
- What the SBA Doesn't Tell You About SBIR Success Rates
- The Difference Between SBIR Winners and SBIR Survivors
- Related Guides
- Sources
The SBIR (Small Business Innovation Research) program has distributed tens of billions of dollars since its creation in 1982. That money produced some of the most recognizable technology companies in the world, and it also funded thousands of projects that never made it past the prototype stage. The difference between these two outcomes is what matters if you're planning to apply.
The proposals that eventually led to commercial success looked different from the ones that didn't, and the differences were visible from Phase I. This guide breaks down 7 SBIR success stories we could confirm in agency records and extracts the patterns you can apply to your own company.
According to SBA, SBIR.gov organizes public success stories by industry and explains Phase III as the commercialization step that follows Phase I and Phase II. According to NIH, small business funding opportunities offer non-dilutive support for early-stage research and development, with applications accepted three times each year. According to NSF, America's Seed Fund awards more than $200 million each year to about 400 startups and small businesses. According to DOE, Phase III work is typically oriented toward commercialization or continued R&D using non-SBIR funding. The official sources are SBIR.gov (opens in a new tab), SBIR commercialization reporting (opens in a new tab), NIH SEED (opens in a new tab), NSF America's Seed Fund (opens in a new tab), and DOE Office of Science SBIR/STTR (opens in a new tab). Our analysis is that the useful lesson from SBIR success stories is not "get a grant," but "use the award to remove a technical risk that blocks a buyer, investor, or government customer."
What official SBIR success-story pages don't tell you is which story is actually transferable to your company. Before deciding to apply, skip, or take a better route, compare SBA success stories, NIH SEED commercialization signals, NSF award and exit data, DOE Phase III examples, agency buyer paths, and company-stage fit. Apply the lesson when the story matches your agency, technical risk, buyer, and follow-on capital path. Skip the comparison when the company only shares a broad sector label. A better route may be customer discovery, agency contact, Phase I proof, Phase II partner, or non-SBIR financing before another proposal.
For example, our review found that a defense robotics story teaches a different lesson than a biomedical platform story. The bad fit is copying a Hall of Fame company because it sounds inspiring. The stronger route is to identify which risk the SBIR removed and whether that same risk blocks your buyer today.
One company in a DOD hardware lane can use a Phase III story to plan procurement contact before Phase II, while one biomedical startup in an NIH lane may need FDA, payer, and investor milestones before the same story is useful. That is why the source owner and buyer path matter more than the famous company name.
June 2026 Source Check: Success Stories Need Status Repair
| Official source checked June 18, 2026 | What it confirms | Grantsights route call |
|---|---|---|
| SBIR.gov success stories and Hall of Fame | Official examples show commercial outcomes across health, defense, space, energy, and software. | Use these as proof that transition can happen, not as a promise that one award creates a company. |
| White House signing notice for S. 3971 | SBIR and STTR were signed back into law on April 13, 2026, authorizing the programs through fiscal year 2031. | Treat SBIR as active, but watch agency due diligence, foreign-risk, submission-limit, and Phase III changes. |
| SBIR.gov performance benchmarks | Phase II awardees update commercialization records at Phase II points and then can update yearly for at least 5 years. | Ask whether a success story has a Phase III, sales, investment, or customer signal, not only a Phase II award. |
| Amazon, FTC, and iRobot bankruptcy records | Amazon and iRobot terminated the planned acquisition in January 2024; iRobot filed a prepackaged Chapter 11 case in December 2025 and was taken over by its lender and manufacturer, Shenzhen PICEA Robotics. | Use iRobot as a product-transition story with a hard ending, not as an exit story. |
| 23andMe investor records | 23andMe entered a court-supervised sale process in 2025, and later asset-sale updates changed the company-status story. | Use 23andMe as a scientific-validation and data-platform warning, not a simple IPO success story. |
| NIH SEED, NSF America's Seed Fund, and DOE SBIR/STTR | Agency pages frame success differently: biomedical validation, startup seed funding, and mission-driven R&D. | Match the example to your agency, buyer, regulatory path, and first non-SBIR money. |
Related guides: compare the SBIR complete guide, first-time applicant guide, SBIR Phase 2 guide, NSF SBIR guide, and the SBIR Phase I index before using a success story in your own proposal strategy.
Get grant deadline alerts by email
About once a week, we email a short list of open grant calls with real deadlines from different funders. It isn't limited to the programs in this guide.
No spam. Unsubscribe anytime.
Current Success-Story Decision Screen
| Searcher question | Best current source | Grantsights answer |
|---|---|---|
| Is SBIR still active? | SBIR.gov and NIH reauthorization notices | Yes, but agency topics, due diligence, and transition rules decide fit. |
| Which story should I copy? | SBIR.gov, NIH SEED, NSF, DOE, and agency success pages | Copy the transition pattern only when the agency buyer, risk, and first non-SBIR money match. |
| What proves success after Phase II? | SBIR.gov commercialization reporting and DOE Phase III examples | Look for sales, Phase III work, private capital, procurement, licensing, or clinical/regulatory progress. |
| When is a famous example misleading? | Company filings and agency pages | A company can validate a technology and still later face business, privacy, market, or financing risk. |
May 2026 Grantsights Decision Memo: Read Success Stories as Transition Evidence
Official SBIR success-story pages are useful because they document public outcomes. SBIR.gov lists story categories such as health, space, defense, energy, genetics, robotics, and commercial success. SBIR.gov commercialization reporting guidance separates Phase III contracts, additional investment, and Phase III sales. That matters because Phase III funding is the clearest signal that the award moved beyond a research subsidy.
According to SBA, the official SBIR success-story database (opens in a new tab) is organized around public commercialization examples, not proposal advice. According to NIH, NIH SEED (opens in a new tab) exists to help biomedical small businesses understand funding and commercialization paths. According to NSF, America's Seed Fund (opens in a new tab) funds startups and small businesses working on high-risk technology. According to DOE, Office of Science SBIR/STTR (opens in a new tab) topics are tied to agency research needs. The Grantsights value is connecting those official source types to the founder's first buyer, not just naming the agencies.
Grantsights' recovery rule for this page is to turn each story into a transition map:
| Success-story signal | Why it matters | How to use it before applying |
|---|---|---|
| Phase I award | Agency believed the technical risk was worth testing | Name the exact uncertainty your Phase I removes |
| Phase II award | Agency believed the prototype or proof path was worth more work | Tie milestones to a buyer, partner, trial, or certification step |
| Phase III contract or sales | Non-SBIR money followed the award | Identify whether your agency can become a buyer or only a validator |
| Private investment | Outside capital accepted the risk reduction | Decide which data point investors need after Phase I or Phase II |
| Public adoption or procurement | Product reached a real operating setting | Show the first user, first buyer, and first deployment path |
A robotics startup selling to defense buyers should study DOD transition and Phase III paths. A health company should study clinical, FDA, payer, and NIH SEED realities. A software company should study security authority, procurement, and agency customer fit. The success story is only valuable when the transition path matches your own.
The SBIR Success Stories Hall of Fame: 7 Companies Worth Studying
Before we analyze patterns, here are 7 SBIR success stories that demonstrate the program's range. We kept only companies whose SBIR or STTR funding shows up in agency records: NSF's small business impacts page (opens in a new tab), NIH RePORTER, SBA testimony to Congress, DOE's SBIR success stories, or NASA award announcements. These companies span agencies, industries, and decades.
| Company | SBIR Agency | Technology Area | Outcome |
|---|---|---|---|
| Qualcomm | NSF | Wireless communications chips | About $180B market value (NSF) |
| iRobot | DOD | Robotics | Roomba breakout; over $10M in DOD SBIR funding (SBA); Chapter 11 and PICEA takeover in 2025-2026 |
| Symantec | NSF | Natural-language software, later security software | Broadcom bought its enterprise security business for $10.7B in 2019 |
| 23andMe | NIH | Genomics/consumer genetics | IPO, large consumer database, later court-supervised asset sale |
| Martek Biosciences | NIH and NSF | Nutritional products from algae and other microbes (DHA) | Acquired by DSM for over $1B in 2011 |
| Giner Inc. | DOE | PEM electrolyzers and hydrogen generation | Over $4M in sales from DOE SBIR-developed products (DOE, 2016) |
| Invocon | NASA | Wireless data acquisition systems | NASA SBIR Phase II selection for a wireless data acquisition system |
These companies represent a tiny fraction of total SBIR awardees, but they illustrate something most people miss: the SBIR program wasn't designed to fund small businesses forever. It was designed to seed technologies that become self-sustaining. The companies on this list understood that.
Best Fit and Bad Fit Checklist for Studying SBIR Success Stories
Use this checklist before copying a success-story playbook. Our analysis is that SBIR success depends on matching the story to your agency, customer, and product timeline.
| Company situation | Best lesson to copy | Bad fit signal |
|---|---|---|
| Deep-tech startup with a technical risk | Use Phase I to prove the risk and Phase II to build a buyer-ready prototype | Proposal treats SBIR as payroll replacement |
| Dual-use defense technology | Study iRobot and DOD Phase III pathways | No agency customer has validated the problem |
| Biotech or diagnostics company | Study NIH-funded companies such as 23andMe and Martek | Timeline ignores FDA, clinical, or reimbursement risk |
| University spinout | Pair SBIR with IP, customer discovery, and investor milestones | Team has publication goals but no commercialization owner |
| Repeat SBIR applicant | Use awards as proof points for private or strategic capital | Company wins multiple awards but has no non-SBIR revenue |
For example, one applicant with a promising sensor technology should not cite iRobot just because both are hardware companies. If the first buyer is a defense customer, the right lesson is DOD topic fit and Phase III contracting. If the first buyer is industrial, the right lesson is private customer validation before Phase II. To compare live SBIR and technology grant opportunities, use the Grantsights grant database.
Qualcomm: The Large-Cap SBIR Success Story
Qualcomm's story is the one that SBIR program advocates cite most often, and for good reason. In the late 1980s, Irwin Jacobs and his team at Qualcomm were developing CDMA (Code Division Multiple Access) technology for wireless communications. The telecom industry thought CDMA was a dead end. The dominant standard was TDMA, and the established players saw no reason to switch.
According to NSF (opens in a new tab), NSF small business grants in the late 1980s helped Qualcomm develop a new type of chip for wireless communications, technology that ended up in most cell phones. The SBA has likewise cited Qualcomm as a company SBIR helped seed in its infancy.
What Qualcomm did differently: They didn't treat SBIR as their business model. SBIR funded the proof-of-concept research, and Qualcomm immediately pursued commercial licensing deals. By the time they went public in 1991, the SBIR-funded research had produced intellectual property that became the foundation for 3G and eventually 4G wireless standards. Qualcomm collected royalties from every phone manufacturer using CDMA-based technology.
The lesson is clear: Qualcomm used SBIR to de-risk a technology that private investors wouldn't touch, then commercialized aggressively once the technology was proven. They never became dependent on government funding.
iRobot: From Military Robots to Roomba
iRobot was founded in 1990 by three MIT roboticists: Colin Angle, Helen Greiner, and Rodney Brooks. Their early work focused on military and space exploration robots. In 2014 testimony to the House Small Business Committee, SBA said iRobot earned over $10 million in SBIR funding from DOD before pivoting its military technology toward consumer products.
The PackBot, iRobot's military robot used for bomb disposal in Iraq and Afghanistan, came out of that defense work. But the commercial breakthrough came when iRobot applied the mobility technology from its military robots to a consumer product: the Roomba vacuum cleaner, launched in 2002.
What iRobot did differently: They recognized that military robotics technology had a consumer application that was much larger than the defense market. The SBIR-funded research solved hard technical problems in mobility, obstacle avoidance, and battery management that transferred directly to the consumer product. Amazon and iRobot later agreed to terminate their proposed $1.4 billion acquisition in January 2024. On December 14, 2025, iRobot filed a prepackaged Chapter 11 case under which its lender and contract manufacturer, Shenzhen PICEA Robotics, acquired the company; common stockholders were wiped out and the stock was delisted. The lesson is product transition and market creation, plus a warning that a successful product doesn't guarantee a lasting company.
For the complete SBIR program overview, including how agencies allocate funding, read our pillar guide. If you're preparing your first application, our first-time applicant guide walks through the process step by step.
Symantec: An NSF SBIR That Led Somewhere Unexpected
Symantec's SBIR roots aren't in security. According to NSF (opens in a new tab), NSF awarded an SBIR grant in 1979 to Machine Intelligence Corp. to improve how computers process language, and that company later became Symantec. NSF has described founder Gary Hendrix's early work as NSF SBIR-funded.
The security business came later. Symantec acquired Peter Norton Computing in 1990 and built the Norton product line into one of the best-known consumer security brands. In 2019, Broadcom bought Symantec's enterprise security business for $10.7 billion; the remaining consumer company renamed itself NortonLifeLock and is now Gen Digital.
What Symantec did differently: The SBIR funded a team and a technical capability, not the final product. The company kept moving toward the market that would pay, even when that meant changing products entirely. That's a useful lesson for founders who treat the Phase I topic as a permanent business plan.
23andMe: NIH SBIR Funding Meets Consumer Genomics
23andMe received NIH SBIR funding to develop genotyping technologies and analytical methods for understanding genetic data. The company, co-founded by Anne Wojcicki in 2006, used SBIR grants to validate its approach to consumer-facing genetic testing at a time when the scientific community questioned whether direct-to-consumer genomics was even appropriate.
NIH SBIR funding helped 23andMe develop the data analysis pipeline that could process genetic samples at scale and return meaningful health and ancestry information to consumers. The company has since processed DNA from over 14 million customers and used its database to make genuine contributions to pharmaceutical research.
What 23andMe did differently: They used NIH SBIR funding to establish scientific credibility in a field where consumer products were viewed skeptically by the research community. The peer-reviewed publications that came from SBIR-funded work gave 23andMe legitimacy with regulators and potential pharmaceutical partners. The later 2025 bankruptcy and asset-sale process shows the other side of the lesson: technical validation and a large data asset do not remove business-model, privacy, and public-company execution risk.
Martek, Giner, and Invocon: Smaller Stories Worth Studying
Not every useful story ends in a household name. According to NSF, numerous NSF small business grants in the 1980s and 1990s helped Martek Biosciences develop nutritional products from algae and other microbes, and NIH RePORTER lists NIH SBIR awards to Martek as well. DSM acquired the company for over $1 billion in 2011.
Giner Inc. shows the DOE path. DOE's own SBIR success story (opens in a new tab) reports over $4 million in sales of products developed through DOE SBIR awards, including on-site hydrogen generation. (Plug Power's 2020 acquisition was of Giner ELX, Giner's electrolyzer spin-off, not Giner Inc. itself.) Invocon, a Texas sensor company, was selected by NASA for Phase II negotiation on a wireless data acquisition system, a typical example of SBIR building a niche government supplier rather than a consumer brand.
For details on how SBIR Phase I connects to Phase II and beyond, see our SBIR Phase I guide.
5 Patterns That SBIR Success Stories Share
Five patterns tend to separate companies with genuine commercial outcomes from those that collect awards and stall out.
Pattern 1: They Treated SBIR as a De-Risking Tool, Not Revenue
Every company on the success list above used SBIR funding to prove something that private investors wouldn't bet on yet. Qualcomm needed to show CDMA worked. iRobot needed to prove autonomous navigation was reliable. 23andMe needed scientific validation for consumer genomics.
None of them built a business model around continuous SBIR funding. The companies that do, sometimes called "SBIR mills," collect Phase I and Phase II awards year after year without ever selling to a non-government customer. SBA applies commercialization benchmarks to repeat awardees, so a long award history with no sales can limit future eligibility.
Pattern 2: They Built Relationships With Program Managers Early
Successful SBIR companies often have a working relationship with their program manager (PM) before they submit their first proposal. This doesn't mean they gamed the system. It means they understood that program managers are looking for technologies that solve specific problems, and a 15-minute conversation with a PM can tell you whether your technology fits their roadmap.
DOD program managers are particularly accessible. They attend industry days, respond to emails, and will tell you directly whether your technology aligns with their priorities. NIH program officers will discuss study sections and suggest appropriate ICs (Institutes and Centers) for your research.
Pattern 3: They Had a Commercialization Plan Before Phase I
In SBIR Phase I proposals, the commercialization section is often the clearest signal of eventual commercial success. Companies that succeed commercially submit Phase I proposals with specific target customers, pricing models, and market entry strategies. Companies that fail commercially submit Phase I proposals that say "we'll figure out commercialization during Phase II."
The SBA has tightened commercialization requirements over the past decade through its Phase II to Phase III commercialization benchmark (opens in a new tab), and DOD separately tracks a Commercialization Achievement Index (CAI). This isn't bureaucratic box-checking. It reflects the reality that companies who think about customers from day one are the ones that build real businesses.
Pattern 4: They Picked the Right Agency for Their Technology
The SBIR program operates across 11 federal agencies, and each agency has different priorities, review processes, and follow-on opportunities. Successful companies matched their technology to the agency most likely to become their first customer or most credible validator.
| Agency | Best For | Average Phase I Award | Follow-On Strength |
|---|---|---|---|
| DOD | Defense applications, dual-use tech | $250,000 | Very strong (Phase III contracts) |
| NIH | Biomedical, diagnostics, therapeutics | $275,000 | Strong (SBIR/STTR Bridge) |
| NSF | Foundational science, deep tech | Up to $305,000 | Moderate (I-Corps connection) |
| DOE | Energy, materials, clean tech | $250,000 | Strong (lab partnerships) |
| NASA | Aerospace, remote sensing | $150,000 | Strong (technology infusion) |
For a detailed comparison of all 11 agencies, see our SBIR agencies comparison guide.
Pattern 5: They Secured Private Investment Alongside or After SBIR
The most successful SBIR companies used their government awards as proof points for private capital. A Phase I award tells angel investors "the federal government reviewed this technology and funded it." A Phase II award with promising results tells VCs "this technology works and has government validation."
23andMe combined SBIR funding with venture capital from Google and others. iRobot attracted strategic investors from the defense industry alongside its SBIR portfolio.
The companies that stayed exclusively in the SBIR pipeline without ever attracting private investment generally had weaker commercial outcomes.
The SBIR Hall of Fame: What It Takes to Get Recognized
The SBA maintains an SBIR Hall of Fame (opens in a new tab) that recognizes companies with exceptional commercialization outcomes from SBIR/STTR funding. Inductees include companies across defense, healthcare, energy, and information technology.
What the Hall of Fame selection criteria reveal is instructive. The SBA doesn't just look at revenue. They evaluate:
- Commercial sales generated from SBIR-funded technologies
- Additional investment attracted (venture capital, strategic partners)
- Job creation resulting from SBIR-funded products
- Social impact of the technology (patents, publications, public benefit)
The Hall of Fame inductees share a common trait: they all transitioned from government-funded R&D to self-sustaining commercial operations. Not a single inductee built their business primarily on continued SBIR awards.
How to Build a Commercialization Track Record From Your First SBIR
If you're applying for your first SBIR award, the success stories above might feel distant. Here's how to start building the commercialization trajectory that separates winners from the rest.
During Phase I (6-12 months):
- Identify 5 to 10 potential customers outside the government and talk to them
- Document letters of support or letters of intent from potential customers
- File provisional patents on any IP generated during research
- Present results at industry conferences, not just academic ones
During Phase II (2 years):
- Generate your first non-SBIR revenue, even if it's a small pilot project
- Build a prototype that you can demonstrate to investors
- Apply for Phase IIB or Sequential Phase II extensions if available
- Start conversations with investors using Phase I/II results as proof points
After Phase II:
- Pursue Phase III contracts (no additional competition required for DOD)
- Apply for SBIR Commercialization Assistance Program (CAP) support
- Use your SBIR track record in private investor pitch decks
- Check whether your state currently offers an SBIR/STTR matching or Phase 0 program; these change often, so confirm with your state economic development office
What the SBA Doesn't Tell You About SBIR Success Rates
The SBA's own data on SBIR commercialization is more nuanced than the headline numbers suggest. Here are things you won't find in the program's marketing materials.
Success rates vary wildly by agency. DOD SBIR projects have the highest reported commercialization rates, partly because the DOD itself is often the buyer through Phase III contracts. NIH SBIR projects take longer to commercialize (biotech timelines) but can produce enormous outcomes when they do. NSF projects fall somewhere in between, with the I-Corps program helping bridge the gap between lab and market.
The definition of "commercialization" is generous. When the SBA reports that a certain percentage of SBIR projects achieve commercialization, that includes companies that generated $10,000 in sales alongside companies that went public. The distribution is highly skewed: a small number of big winners drive the aggregate numbers.
Many Phase I awardees never reach Phase II. Phase II is a separate competition, and agencies fund fewer Phase II awards than Phase I awards. Of the projects that do reach Phase II, only some achieve meaningful commercial traction. Plan for the odds to narrow at each step.
Repeat awardees aren't always a good sign. Some companies win 20 or more SBIR awards and never generate meaningful commercial sales. The SBA has tried to address this with its commercialization benchmark, which can bar companies with many past awards and too little commercial result from new Phase I awards for a period. If you're a first-time applicant, this actually works in your favor.
Agency relationships matter more than proposal writing quality. A well-written proposal submitted to the wrong program or topic will lose to a decent proposal that perfectly addresses the program manager's actual needs. Talking to the program manager before submitting is the cheapest way to find out which side of that line you're on.
The Difference Between SBIR Winners and SBIR Survivors
There's an important distinction between companies that win SBIR awards and companies that build successful businesses from SBIR-funded technology. The SBIR program funds over 6,000 new projects per year across all agencies. Most produce valid research results. Most advance the state of the art in their technical area. But only a fraction produce commercial products or services.
The difference isn't technical ability. The companies that stall out often have excellent scientists and engineers. What they lack is commercial intent from the beginning. They treat SBIR as an academic research grant rather than a business development tool. They publish papers instead of filing patents. They attend scientific conferences instead of trade shows. They hire more researchers instead of salespeople.
The success stories in this guide did the opposite. They hired business development staff early. They talked to customers before they had a product. They used SBIR as a runway to become commercially viable, not as an end in itself.
If you're considering SBIR, be honest about which category you're in. Do you want to build a business, or do you want to fund research? Both are valid goals, but SBIR is designed for the first one.
Related Guides
Sources
- SBA SBIR/STTR Program Overview: https://www.sbir.gov (opens in a new tab)
- SBA SBIR Success Stories: https://www.sbir.gov/success-stories (opens in a new tab)
- National Research Council, "An Assessment of the SBIR Program," National Academies Press
- SBA SBIR Hall of Fame: https://www.sbir.gov/success-stories (opens in a new tab)
- Amazon and iRobot termination announcement: https://www.aboutamazon.com/news/company-news/amazon-irobot-terminate-acquisition (opens in a new tab)
- FTC statement on Amazon and iRobot termination: https://www.ftc.gov/news-events/news/press-releases/2024/01/statement-regarding-termination-amazons-proposed-acquisition-irobot (opens in a new tab)
- Qualcomm corporate history and SEC filings
- iRobot SEC filings and Amazon acquisition documents
- 23andMe SEC filings and GlaxoSmithKline partnership disclosures
- 23andMe investor press releases: https://investors.23andme.com/news-events/press-releases/ (opens in a new tab)
- NSF small business impacts (Qualcomm, Symantec, Martek): https://www.nsf.gov/impacts/small-business (opens in a new tab)
- SBA testimony to the House Small Business Committee, July 23, 2014 (iRobot, Qualcomm, Symantec): https://smallbusiness.house.gov/uploadedfiles/7-23-2014_saade_updated_testimony.pdf (opens in a new tab)
- DOE SBIR success story, Giner Inc.: https://science.osti.gov/-/media/sbir/pdf/Success-Stories/Giner-Inc_EERE_2016.pdf (opens in a new tab)
- NIH RePORTER award records for 23andMe and Martek: https://reporter.nih.gov (opens in a new tab)
- iRobot Chapter 11 and PICEA acquisition: https://www.nasdaq.com/articles/irobot-commences-bankruptcy-process-and-agrees-acquisition-picea (opens in a new tab)
- SBIR.gov award database for individual company award histories
- GAO Report on SBIR Commercialization (GAO-22-105081)
- National Academies of Sciences, "SBIR/STTR at the Department of Defense," 2022
Next steps
Start your own SBIR application
These next pages help you move from research into a specific grant choice.
SBIR overview
Use when a success story needs to be translated into phase, eligibility, and agency fit.
First applicant
Turn example-company lessons into registrations, agency choice, and first proposal steps.
Phase II route
Check whether proof, milestones, and buyer evidence can support the next award stage.
NSF SBIR
Use when the company is a deep-tech startup rather than a mission-agency contractor.
Phase I index
Compare active SBIR Phase I paths after the success-story lesson is clear.
Federal Program Records to Compare
Use these current program records to check eligibility, award history, deadlines, and past winners before your team commits writing time.
- Oral Diseases and Disorders Research - SBIR/STTRHHS · Closed
- Small Business Innovation Research Program (SBIR) Phase IIHHS · Upcoming
- Small Business Innovation Research (SBIR) program, Phase IHHS · Upcoming
- NOAA Small Business Innovation Research (SBIR) ProgramDOC · Open
- Small Business Innovation Research (SBIR) Program / Small Business Technology Transfer (STTR) ProgramUSDA · Open
Frequently Asked Questions
How many SBIR companies actually succeed commercially?
The honest answer depends on how you define success. The National Research Council's multi-year assessments surveyed Phase II awardees about sales and investment, and many reported reaching the market in some form. But 'commercialization' can mean anything from $50,000 in product sales to a billion-dollar IPO, and the companies that generate substantial revenue are a much smaller slice. DOD projects can have a shorter path because the awarding agency is often the first customer. NIH SBIR projects take longer to commercialize because biotech products face years of FDA regulatory review after the research phase ends.
What makes an SBIR company successful after the grant ends?
The pattern across successful SBIR companies is surprisingly consistent. They treat the SBIR as a de-risking tool rather than a revenue source, meaning they're already thinking about customers during Phase I. They build relationships with the program managers at their awarding agency, which opens doors to Phase III contracts and follow-on work. They use the SBIR to generate proof-of-concept data that makes them fundable by private investors. And they don't rely on SBIR funding forever. Companies that chain together six or seven SBIR awards without ever selling a product to a real customer are what insiders call 'SBIR mills,' and they rarely build lasting businesses.
Can I still get SBIR funding if I'm not a tech startup?
Yes, but you need to understand that SBIR is fundamentally a research and development program. You need to propose genuine technical innovation, not just a business idea. Successful SBIR applicants in non-traditional tech sectors include agricultural technology companies (USDA SBIR), environmental remediation firms (EPA SBIR), educational technology developers (ED SBIR), and transportation safety companies (DOT SBIR). The common thread is that they all proposed measurable R&D with a clear path to a product or service. If your business doesn't involve developing new technology or a new application of existing technology, SBIR probably isn't the right fit.
How did Qualcomm use SBIR funding early on?
According to NSF, NSF small business grants in the late 1980s helped Qualcomm, then a startup, develop a new type of chip for wireless communications that ended up in most cell phones. The SBA has also named Qualcomm among the companies SBIR helped seed in their infancy. Qualcomm went public in 1991 and built a wireless licensing and chip business on top of that early R&D. NSF puts its market value at about $180 billion.
Is SBIR funding drying up under recent budget cuts?
The SBIR program has faced political and authorization pressure, but it remains a major federal R&D route for small businesses. The 2026 reauthorization extended SBIR and STTR through September 30, 2031, while keeping the agency set-aside model that directs more than $4 billion per year across participating agencies. That said, individual agencies still shift topics, due diligence rules, foreign-risk reviews, and transition priorities. The best strategy is to monitor multiple agencies rather than depending on a single one.
Last updated October 10, 2026. Corrected October 10, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
Complete Guide
SBIR Grants 2026: Phase I, Phase II, STTR, NIH, NSF
Compare SBIR Phase I, Phase II, STTR, NIH, NSF, rural business, and production paths, with award caps, before choosing an agency.
How to Write an SBIR Proposal (2026 Guide)
Write an SBIR proposal that survives review: 5 core sections, scoring criteria, NIH and NSF font rules, and agency-specific review signals.
NSF SBIR Guide 2026: Win America's Seed Fund
NSF SBIR Phase I pays up to $305K and Phase II up to $1.25M. See how NSF differs from NIH, Fast-Track, the review process, and application tips.
NIAID R01 Success Rate: FY2024 and FY2025 Data
NIAID funded 15.8% of R01-equivalent applications in FY2024 by its own count, and NIH tables show 14.5% for FY2025. See paylines and FY2026 awards.
NIH F31 Success Rate by Institute: FY2025 Data
The NIH F31 success rate fell to 23.5% in FY2025 (849 of 3,607). Rates ranged from 13.4% at NIA to 44.8% at NIDCD. See every institute and FY2026 awards.
NIH F32 Success Rate FY2025: 26.4%, by Institute
The NIH F32 success rate fell to 26.4% in FY2025 (319 of 1,210), from 32.9%. See rates by degree and institute, plus 242 new FY2026 F32 award records.